Regeneron Pharmaceuticals Financial Statements Trends

REGN -- USA Stock  

Earning Report: November 5, 2019  

This module enables investors to look at Regeneron Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 311.7 M, Consolidated Income of 476.6 M or Cost of Revenue of 175.6 M, but also many exotic indicators such as Interest Coverage of 77.0381, Long Term Debt to Equity of 0.196 or Calculated Tax Rate of 10.7856. This module is a perfect complement to use when analyzing Regeneron Pharmaceuticals Valuation or Volatility. It can also complement various Regeneron Pharmaceuticals Technical models. Additionally take a look at analysis of Regeneron Pharmaceuticals Correlation with competitors.
Revenues

Regeneron Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.6 B11.7 B4.3 B
Increasing
Slightly volatile
Cash and Equivalents2.7 B1.5 B726.6 M
Increasing
Slightly volatile
Investments827.5 M1.2 B707.9 M
Increasing
Slightly volatile
Investments Current319.3 M453.1 M246.3 M
Increasing
Slightly volatile
Investments Non Current508.2 M777.8 M461.6 M
Increasing
Slightly volatile
Deferred Revenue616.2 M956.2 M504.3 M
Increasing
Slightly volatile
Property Plant and Equipment Net1.2 B1.9 B975.5 M
Increasing
Slightly volatile
Inventory229.5 M359.4 M175.9 M
Increasing
Slightly volatile
Tax Assets577.8 M742.8 M477.2 M
Increasing
Slightly volatile
Trade and Non Trade Receivables924.4 M1.5 B828.7 M
Increasing
Slightly volatile
Trade and Non Trade Payables489.3 M791.2 M395.1 M
Increasing
Slightly volatile
Total Liabilities2.2 BB1.5 B
Increasing
Slightly volatile
Shareholders Equity5.9 B8.8 BB
Increasing
Slightly volatile
Accumulated Retained Earnings Deficit677.3 M1.6 B221.1 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(5 M)(11.6 M)1.2 M
Decreasing
Stable
Current Assets2.9 B6.4 B2.2 B
Increasing
Slightly volatile
Assets Non Current2.1 B3.4 B1.8 B
Increasing
Slightly volatile
Current Liabilities811.2 M1.4 B583.6 M
Increasing
Slightly volatile
Liabilities Non Current812 M1.2 B773.3 M
Increasing
Slightly volatile
Total Debt711.3 M431 M399 M
Increasing
Slightly volatile
Debt Current78.4 M114.5 M69.5 M
Increasing
Slightly volatile
Debt Non Current287.9 M316.4 M332.6 M
Increasing
Slightly volatile
Shareholders Equity USD2.6 BB2.2 B
Increasing
Slightly volatile
Cash and Equivalents USD392.4 M481.7 M434.9 M
Increasing
Slightly volatile
Total Debt USD349.8 M431 M368.8 M
Increasing
Slightly volatile
Accounts Payable154.2 M218.2 M92.3 M
Increasing
Slightly volatile
Receivables1.2 B1.7 B763.8 M
Increasing
Slightly volatile
Inventories796.4 M1.2 B321.9 M
Increasing
Slightly volatile

Regeneron Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues7.2 B6.7 B3.1 B
Increasing
Slightly volatile
Cost of Revenue175.6 M269.7 M158.1 M
Increasing
Slightly volatile
Selling General and Administrative Expense650.5 M1.1 B518.8 M
Increasing
Slightly volatile
Research and Development Expense1.2 B1.8 B1.1 B
Increasing
Slightly volatile
Operating Expenses1.9 B2.9 B1.6 B
Increasing
Slightly volatile
Interest Expense10.4 M6.5 M17.5 M
Decreasing
Very volatile
Income Tax Expense278.9 M390.9 M207.8 M
Increasing
Slightly volatile
Consolidated Income476.6 M806 M395.1 M
Increasing
Slightly volatile
Net Income2.1 B2.4 B692.1 M
Increasing
Slightly volatile
Net Income Common Stock476.6 M806 M395.1 M
Increasing
Slightly volatile
Weighted Average Shares108 M107.9 M96.4 M
Increasing
Slightly volatile
Weighted Average Shares Diluted104.9 M114.8 M103.4 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT729.3 M1.2 B617.2 M
Increasing
Slightly volatile
Revenues USD2.8 B4.4 B2.4 B
Increasing
Slightly volatile
Net Income Common Stock USD476.6 M806 M395.1 M
Increasing
Slightly volatile
Earning Before Interest and Taxes USD729.3 M1.2 B617.2 M
Increasing
Slightly volatile
Gross Profit4.1 B4.1 B2.3 B
Increasing
Slightly volatile
Operating Income1.7 B2.5 B875.8 M
Increasing
Slightly volatile
Direct Expenses311.7 M434.1 M190.8 M
Increasing
Slightly volatile

Regeneron Pharmaceuticals Cash Flow Statement

Trends Matrix
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditure(386.7 M)(588.7 M)(289.9 M)
Decreasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals(369.6 M)(615.2 M)(227.2 M)
Decreasing
Slightly volatile
Net Cash Flow from Financing(77.4 M)(77.1 M)(56.8 M)
Decreasing
Slightly volatile
Issuance Repayment of Debt Securities (22 M)(46.7 M)11.1 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares13.4 M(18.9 M)909 K
Decreasing
Slightly volatile
Net Cash Flow from Investing(1.1 B)(1.5 B)(556.6 M)
Decreasing
Slightly volatile
Net Cash Flow from Operations1.1 B2.2 B707.4 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(146.3 M)(315 M)(19.3 M)
Decreasing
Slightly volatile
Share Based Compensation314.8 M503.9 M263.1 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion62 M94.3 M53.6 M
Increasing
Slightly volatile

Fundamental Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share14.436822.656.1147
Increasing
Slightly volatile
Earnings per Diluted Share18.021.295.9225
Increasing
Slightly volatile
Earnings per Basic Share USD4.40957.73.71
Increasing
Slightly volatile
Return on Average Equity0.244332.807710.6165
Increasing
Slightly volatile
Return on Average Assets0.115723.84927.415
Increasing
Slightly volatile
Return on Invested Capital0.10890.23220.1001
Increasing
Slightly volatile
Gross Margin10493.531396.008
Decreasing
Stable
Profit Margin0.285936.42495.8094
Increasing
Slightly volatile
EBITDA Margin28.788540.618115.8486
Increasing
Slightly volatile
Return on Sales(0.2076)0.2475(0.194)
Increasing
Slightly volatile
Asset Turnover0.63580.65480.6742
Increasing
Slightly volatile
Enterprise Value over EBITDA12.408523.8311.514
Increasing
Slightly volatile
Enterprise Value over EBIT14.447425.214.5539
Increasing
Slightly volatile
Price to Earnings Ratio16.6738.6428.7706
Increasing
Slightly volatile
Sales per Share44.639362.194627.6803
Increasing
Slightly volatile
Price to Sales Ratio4.569.113.3863
Decreasing
Slightly volatile
Price to Book Value3.367.839.4084
Increasing
Very volatile
Debt to Equity Ratio7.20.08090.8465
Increasing
Slightly volatile
Current Ratio3.884.46884.3164
Decreasing
Stable
Free Cash Flow per Share24.416.79335.5885
Increasing
Slightly volatile
Book Value per Share24.905338.0921.9275
Increasing
Slightly volatile
Tangible Assets Book Value per Share39.936859.7135.2708
Increasing
Slightly volatile
Total Assets Per Share74.878810843.0711
Increasing
Slightly volatile
Cash Flow Per Share13.540720.13746.8793
Increasing
Slightly volatile
Return on Investment23.769231.071515.3209
Increasing
Slightly volatile
Operating Margin32.0837.76612.9891
Increasing
Slightly volatile
Calculated Tax Rate10.78564.2726(14.2853)
Increasing
Slightly volatile
Receivables Turnover17.44434.114136.6799
Decreasing
Slightly volatile
Inventory Turnover0.97330.46251.6355
Decreasing
Slightly volatile
PPandE Turnover2.61942.722.7511
Increasing
Stable
Cash and Equivalents Turnover5.10295.88554.5296
Increasing
Slightly volatile
Accounts Payable Turnover31.984333.860233.2356
Increasing
Slightly volatile
Accrued Expenses Turnover12.17379.6712.4956
Decreasing
Slightly volatile
Interest Coverage77.038189.872350.99
Increasing
Slightly volatile
Long Term Debt to Equity0.1960.08090.26
Decreasing
Slightly volatile
Quick Ratio3.57493.14223.3687
Decreasing
Stable
Net Current Assets as percentage of Total Assets45.031742.650339.9958
Decreasing
Very volatile
Revenue to Assets0.55550.57190.5926
Increasing
Slightly volatile

Regeneron Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax718.9 M1.2 B599.7 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA2.3 B2.7 B987.8 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD791.3 M1.3 B670.8 M
Increasing
Slightly volatile
Market Capitalization33 B34.8 B24.9 B
Increasing
Slightly volatile
Enterprise Value30.8 B34.4 B24.5 B
Increasing
Slightly volatile
Invested Capital2.9 B4.5 B2.7 B
Increasing
Slightly volatile
Average Equity2.4 B3.8 BB
Increasing
Slightly volatile
Average Assets3.8 B5.8 B3.2 B
Increasing
Slightly volatile
Invested Capital AverageB4.7 B2.6 B
Increasing
Slightly volatile
Tangible Asset Value4.1 B6.3 B3.5 B
Increasing
Slightly volatile
Free Cash Flow496.9 M865.3 M352.8 M
Increasing
Slightly volatile
Working Capital2.1 B1.7 B1.3 B
Increasing
Slightly volatile
Revenue Per Employee781.9 K906.9 K698.7 K
Increasing
Slightly volatile
Net Income Per Employee226.5 K330.3 K117.6 K
Increasing
Slightly volatile

Regeneron Pharmaceuticals Fundamental Market Drivers

Short Percent Of Float2.84%
Forward Price Earnings11.94
Shares Short Prior Month2.33M
Average Daily Volume Last 10 Day798.89k
Average Daily Volume In Three Month697.26k
Date Short InterestSeptember 30, 2019
Fifty Day Average288.08
Two Hundred Day Average311.33

Regeneron Pharmaceuticals Upcoming Events

Upcoming Quarterly Earning ReportNovember 5, 2019
Next Earnings ReportFebruary 5, 2020
Next Fiscal Quarter EndSeptember 30, 2019
Next Fiscal Year EndFebruary 5, 2020
Last Quarter Report DateJune 30, 2019
Last Earning Anouncement DateSeptember 30, 2018
Search macroaxis.com